Phathom Pharmaceuticals, Inc.
PHAT
$10.58
-$0.21-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.44% | 60.46% | 19.62% | -26.68% | 13.00% |
| Total Depreciation and Amortization | -17.95% | -9.30% | -2.82% | -8.29% | 1.05% |
| Total Amortization of Deferred Charges | 4.39% | 5.59% | 5.46% | 10.65% | 6.79% |
| Total Other Non-Cash Items | -32.27% | -9.06% | 4.01% | -9.28% | -3.18% |
| Change in Net Operating Assets | 359.86% | 73.84% | 33.24% | 1.35% | -752.42% |
| Cash from Operations | 64.57% | 77.50% | 26.14% | -33.84% | 0.18% |
| Capital Expenditure | -222.22% | 72.16% | -438.89% | -260.00% | 88.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -222.22% | 72.16% | -438.89% | -260.00% | 88.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 331.74% | 266.25% | -- | -- | -98.94% |
| Repurchase of Common Stock | -141.49% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 64.21% | -438.75% | -- | -- | -78.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 64.03% | 77.03% | 26.14% | -127.04% | -164.02% |